Cargando…
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response. In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response. Immune checkpoint therapies act by blocking or stimulating thes...
Autores principales: | Marin-Acevedo, Julian A., Dholaria, Bhagirathbhai, Soyano, Aixa E., Knutson, Keith L., Chumsri, Saranya, Lou, Yanyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856308/ https://www.ncbi.nlm.nih.gov/pubmed/29544515 http://dx.doi.org/10.1186/s13045-018-0582-8 |
Ejemplares similares
-
Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018) -
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
por: Soyano, Aixa E., et al.
Publicado: (2018) -
Next generation of immune checkpoint inhibitors and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021) -
Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017) -
Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
por: Lou, Yanyan, et al.
Publicado: (2018)